Phathom Pharmaceuticals Inc., a biopharmaceutical company focusing on gastrointestinal disease treatments, has announced the approval of new inducement awards for Jonathan Bentley, who has been appointed as Senior Vice President, Head of Sales. On May 1, 2025, the company's Board of Directors granted Bentley a non-qualified stock option to purchase 79,365 shares of common stock, with 25% vesting on May 1, 2026, and the rest vesting in 36 equal monthly installments. Additionally, Bentley received two restricted stock unit awards: 57,143 units vesting in three equal annual installments and 50,000 units vesting in two equal installments. These awards are part of the 2025 Employment Inducement Incentive Award Plan and are contingent on Bentley's continued service with the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.